A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.

Trial Details

NCT ID
NCT06497985
Phase
PHASE3
Sponsor
Chipscreen Biosciences, Ltd.
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Tucidinostat
  • Sintilimab
  • Bevacizumab
  • Fruquintinib
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Provide written informed consent for the study.
  • Age ≥18 years and ≤75 years.
  • Histologically or cytologically confirmed unresectable and metastatic colorectal adenocarcinoma.
  • Has been previously treated and has shown disease progression or could not tolerate standard treatment, which must include fluoropyrimidine, irinot…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →